# ğŸ“… Daily Report - 2025-11-18

> ä»Šæ—¥ç­›é€‰å‡º **35** æ¡å†…å®¹ï¼Œæ¥è‡ª **4** ä¸ªæ¥æº

<div class="powered-by-top">Powered by <a href="https://kyplus.de">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai">Claude</a></div>

---

## ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“

### ğŸ“° å…¬ä¼—å·

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
å•ç»†èƒ+ç©ºè½¬å¤šç»„å­¦æ­ç¤ºCTCF+TANå’ŒVSIG4+S100A10+å·¨å™¬ç»†èƒåœ¨å…ç–«æ²»ç–—ä¸­çš„å…³é”®ä½œç”¨ï¼Œå¹¶å‘ç°å¹²æ‰°ç´ è¯±å¯¼çš„è¡°è€CD8Tç»†èƒå½±å“å…ç–«æ²»ç–—ç–—æ•ˆã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- å…ç–«ç»†èƒäºšå‹ï¼ˆä¸­æ€§ç²’ç»†èƒã€å·¨å™¬ç»†èƒã€CD8Tç»†èƒï¼‰ä¸å…ç–«æ²»ç–—ç–—æ•ˆçš„å…³ç³»
- è‚¿ç˜¤ç»†èƒä¼‘çœ æœºåˆ¶åŠå¹²é¢„ç­–ç•¥ï¼ˆå¦‚WNTé€šè·¯ã€åŒ–ç–—ï¼‰
- è¡°è€åœ¨æŠ—ç™Œä¸­çš„æ½œåœ¨ç›Šå¤„
- è‚ºç™Œè½¬ç§»çš„å…ç–«æ²»ç–—æ–°ç­–ç•¥

**æŠ€æœ¯äº®ç‚¹**ï¼š
- æ–°å‹ç©ºé—´è½¬å½•ç»„åˆ†ææ–¹æ³•ï¼ˆæ— éœ€è®¾å¤‡ï¼‰
- é«˜æ•ˆå•ç»†èƒæ•°æ®åˆ†ææŠ€æœ¯ï¼ˆBPCellsï¼‰
- æ•´åˆå¤šæ•°æ®é›†æ„å»ºå¤§è§„æ¨¡ã€å¤šå±‚æ¬¡äººç±»è‚ºéƒ¨å•ç»†èƒå›¾è°±

### ğŸ§¬ æ•°æ®å‰æ²¿

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
ABCA1è›‹ç™½åœ¨å¢å¼ºé«“ç³»å…ç–«ç»†èƒæŠ—ç™ŒåŠŸèƒ½ä¸­èµ·å…³é”®ä½œç”¨ï¼›TFAé€šè¿‡STAT3/EMTé€šè·¯æŠ‘åˆ¶ç»“ç›´è‚ ç™Œè½¬ç§»ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- å…ç–«è‚¿ç˜¤å­¦ï¼šABCA1è›‹ç™½å¯¹è‚¿ç˜¤å…ç–«çš„è°ƒæ§æœºåˆ¶ã€‚
- ç™Œç—‡ä¿¡å·é€šè·¯ï¼šTFAå¯¹STAT3/EMTé€šè·¯çš„æŠ‘åˆ¶ä½œç”¨åŠå…¶åœ¨ç»“ç›´è‚ ç™Œè½¬ç§»ä¸­çš„å½±å“ã€‚
- æ¤ç‰©è½¬å½•è°ƒæ§ï¼šLUMINIDEPENDENSè›‹ç™½åœ¨æ‹Ÿå—èŠ¥ä¸­çš„è½¬å½•æŠ‘åˆ¶åŠŸèƒ½ã€‚
- ç»†èƒåˆ†åŒ–ï¼šå«æ˜Ÿç»†èƒåˆ†åŒ–è¿‡ç¨‹ä¸­çš„RNAè°ƒæ§æœºåˆ¶ã€‚
- é—ä¼ ç–¾ç—…ï¼šé’ˆå¯¹è„Šé«“æ€§è‚Œèç¼©ç—‡ï¼ˆSMAï¼‰çš„é¶å‘åä¹‰å¯¡æ ¸è‹·é…¸æ²»ç–—æ•ˆæœã€‚
- è‚¿ç˜¤å‘ç”Ÿä¸å…ç–«ï¼šATF6Î±åœ¨è‚ç»†èƒç™Œï¼ˆHCCï¼‰ä¸­é€šè¿‡è¯±å¯¼ERåº”æ¿€é™åˆ¶å…ç–«ç›‘è§†ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
- é«˜é€šé‡æµ‹åºæŠ€æœ¯ï¼ˆGenome binding/occupancy profiling, Expression profiling, ChIP-Seq, scRNA-seq, bulk RNA-seqï¼‰åœ¨å¤šé¡¹ç ”ç©¶ä¸­å¾—åˆ°å¹¿æ³›åº”ç”¨ï¼Œæ·±å…¥è§£æåŸºå› ç»„ã€è½¬å½•ç»„åŠè›‹ç™½è´¨åŠŸèƒ½ã€‚

### ğŸ”¬ æœŸåˆŠæ–‡ç« 

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š

ASCOæ›´æ–°äº†å…¶å…³äºæ¥å—å…¨èº«æ€§ç™Œç—‡æ²»ç–—çš„è€å¹´æ‚£è€…è„†å¼±æ€§è¯„ä¼°å’Œç®¡ç†çš„æŒ‡å—ã€‚

**ä¸»è¦æ–¹å‘**ï¼š

*   è¯„ä¼°è€å¹´ç™Œç—‡æ‚£è€…çš„è„†å¼±æ€§ã€‚
*   ç®¡ç†æ¥å—å…¨èº«æ€§ç™Œç—‡æ²»ç–—çš„è€å¹´æ‚£è€…çš„è„†å¼±æ€§ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š

*   æŒ‡å—æ›´æ–°ï¼Œæä¾›ä¸´åºŠå®è·µå»ºè®®ã€‚

### ğŸ§ª åšå®¢æ›´æ–°

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
é¦–æ¬¡å‘ç°ä¸€ç±»æ–°å‹Tè¾…åŠ©ç»†èƒï¼Œèƒ½æ¸…é™¤è¡°è€ç»†èƒï¼Œå¯èƒ½å»¶ç¼“è¡°è€ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- è¯†åˆ«æ–°å‹Tè¾…åŠ©ç»†èƒåœ¨æŠµæŠ—è¡°è€ä¸­çš„ä½œç”¨æœºåˆ¶ã€‚
- æ¢ç´¢è¯¥ç»†èƒç¾¤åœ¨è¶…ç™¾å²è€äººä¸­çš„é«˜ä¸°åº¦åŠå…¶å¥åº·ç›Šå¤„ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
- å‘ç°æ–°å‹Tè¾…åŠ©ç»†èƒäºšç¾¤ã€‚
- é€šè¿‡æ¸…é™¤è¡°è€ç»†èƒå®ç°æŠ—è¡°è€ã€‚

---

## ğŸ“š åˆ†ç±»æµè§ˆ

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“° å…¬ä¼—å· (23æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰

**1.** â­ **æœ€æ–°10åˆ†ç”Ÿä¿¡ï¼Œå•ç»†èƒ+ç©ºè½¬å¤šç»„å­¦è¿›è¡Œä¸­æ€§ç²’ç»†èƒäºšå‹åˆ†æï¼Œè¯†åˆ« CTCF+TANï¼Œé¶å‘CTCFæ”¹å–„å…ç–«æ²»ç–—ç–—æ•ˆï¼**
- âœï¸ **ä½œè€…**ï¼šä¸œæ™“ç”Ÿç‰©
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå…ç–«ã€å•ç»†èƒã€ç”Ÿä¿¡
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg2OTU2MzM2NA==&mid=2247493020&idx=1&sn=a438e8048b74f33cc1195653f68e0f68)

**2.** â­ **8.5ç”Ÿä¿¡ï¼Œé‰´å®šVSIG4+S100A10+å·¨å™¬ç»†èƒï¼Œå½±å“å…ç–«æŠ‘åˆ¶åŠå…ç–«æ²»ç–—ç–—æ•ˆã€‚å•ç»†èƒç»“åˆç©ºè½¬åˆ†æå¯å¢åŠ ç»“æœå¯ä¿¡åº¦ï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå…ç–«ã€å•ç»†èƒã€ç”Ÿä¿¡
- ğŸ“ **æè¿°**ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503966&idx=3&sn=88fd503b4f4e997329b0fefff4115a89)

**3.** â­ **SMTdbï¼šç™Œç—‡ç©ºé—´å…ƒè½¬å½•ç»„èµ„æº**
- âœï¸ **ä½œè€…**ï¼šBMELab
- ğŸ·ï¸ **å…³é”®è¯**ï¼šç™Œç—‡ã€ç©ºé—´è½¬å½•ç»„ã€è½¬å½•ç»„
- ğŸ“ **æè¿°**ï¼šSMTdbï¼šç™Œç—‡æ—¶ç©ºè½¬å½•ç»„èµ„æº
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzkyNDI1MzE0NA==&mid=2247490149&idx=1&sn=51acdbfaffdea908313eb24f23713987)

**4.** â­ **æ–‡çŒ®åˆ†äº«--ç—…ç¶ä¿®å¤è¿‡ç¨‹ä¸­å¿ƒè„å…ç–«å¾®ç¯å¢ƒçš„æ—¶ç©ºåŠ¨æ€å˜åŒ–**
- âœï¸ **ä½œè€…**ï¼šå•ç»†èƒç©ºé—´äº¤å“ä¹
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå…ç–«ã€å…ç–«å¾®ç¯å¢ƒã€å¿ƒè„
- ğŸ“ **æè¿°**ï¼šæ–‡çŒ®åˆ†äº«--ç—…ç¶ä¿®å¤è¿‡ç¨‹ä¸­å¿ƒè„å…ç–«å¾®ç¯å¢ƒçš„æ—¶ç©ºåŠ¨æ€å˜åŒ–
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg2MDY1NTYyOQ==&mid=2247498970&idx=1&sn=dfa567268fe92b7f10c56e9c0aaf6a65)

**5.** **æœ€æ–°14+å¹²æ¹¿ç»“åˆSCIï¼Œä½œè€…é‰´å®šå‡ºå¹²æ‰°ç´ è¯±å¯¼çš„è¡°è€ CD8T ç»†èƒå¹¶æ­ç¤ºå…¶å¯¹å…ç–«æ²»ç–—çš„å½±å“ã€‚è¡°è€è™½è€ï¼Œä½†æ˜¯çœŸçš„ç«ï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå…ç–«ã€è¡°è€
- ğŸ“ **æè¿°**ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503966&idx=2&sn=a75e4468548c5160364be04dc1e096bd)

**6.** **44.5åˆ†é¡¶åˆŠå‘æ–‡ï¼Œå•ç»†èƒé‰´å®šå‡ºä¹æ°§å·¨å™¬ç»†èƒè¿›è¡Œåç»­ç ”ç©¶ã€‚å‰æœ‰è¡°è€CD8Tï¼Œç°æœ‰ä¹æ°§å·¨å™¬ã€‚è¯†åˆ«æŸç§è¡¨å‹çš„XXç»†èƒå¯å‘é«˜åˆ†æ–‡ç« ï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè¡°è€ã€å•ç»†èƒ
- ğŸ“ **æè¿°**ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503966&idx=1&sn=166d7720afa95a4f96c0110de0928633)

**7.** **è¡°è€ç«Ÿèƒ½æŠ‘åˆ¶ç™Œç—‡ï¼ã€Šè‡ªç„¶ã€‹å­åˆŠï¼šæ´»åˆ°ä¸€å®šå²æ•°ï¼Œèº«ä½“ä¼šå¼€å¯æŠ—ç™Œæ¨¡å¼**
- âœï¸ **ä½œè€…**ï¼šå­¦æœ¯ç»çº¬
- ğŸ·ï¸ **å…³é”®è¯**ï¼šç™Œç—‡ã€è¡°è€
- ğŸ“ **æè¿°**ï¼šè¡°è€çš„"æ„å¤–ç›Šå¤„"
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&mid=2247568932&idx=1&sn=58c3aee0ef98549a37a6b8c8ada229e2)

**8.** **CRï¼šè¯†ç ´è‚¿ç˜¤ç»†èƒçš„â€œè£…æ­»â€è®¡è°‹ï¼ç§‘å­¦å®¶å‘ç°ï¼ŒåŒ–ç–—æ¿€æ´»WNTé€šè·¯æ˜¯ä¹³è…ºç™Œç»†èƒè¿›å…¥ä¼‘çœ çŠ¶æ€çš„å…³é”®**
- âœï¸ **ä½œè€…**ï¼šå¥‡ç‚¹è‚¿ç˜¤æ¢ç§˜
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤ã€é€šè·¯
- ğŸ“ **æè¿°**ï¼šè‚¿ç˜¤ç»†èƒé†’é†’ï¼Œè¿™é‡Œä¸è®©ç¡
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzI4ODc5MDI5NA==&mid=2247503499&idx=1&sn=7c356ba124ce4c2389679cf3a0941c66)

**9.** **å®éªŒå¯¹è±¡å¤ªçè´µï¼ŸNature Methods éªŒè¯ï¼šæ— éœ€è®¾å¤‡åˆ†æç©ºé—´è½¬å½•ç»„**
- âœï¸ **ä½œè€…**ï¼šä¸é¦™å­¦æœ¯
- ğŸ·ï¸ **å…³é”®è¯**ï¼šç©ºé—´è½¬å½•ç»„ã€è½¬å½•ç»„
- ğŸ“ **æè¿°**ï¼šæŠ¥åç›´æ’­ï¼Œèµ¢æƒŠå–œå¥½ç¤¼ï¼
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&mid=2247650143&idx=2&sn=b74ae75a5cf945d50a6015f17184241d)

**10.** **ä¹³è…ºç™Œè‚ºè½¬ç§»æ–°æœºåˆ¶ï¼é‡åº†åŒ»ç§‘å¤§å­¦å‘æ–‡ï¼šä¸´åºŠè‚¿ç˜¤å…ç–«æ²»ç–—çš„æœ‰æ•ˆç­–ç•¥**
- âœï¸ **ä½œè€…**ï¼šè½¬åŒ–åŒ»å­¦ç½‘
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤ã€å…ç–«
- ğŸ“ **æè¿°**ï¼šæœ¬ç ”ç©¶å·¥ä½œæˆ–è®¸èƒ½ä¸ºæ²»ç–—ä¹³è…ºç™Œè‚ºè½¬ç§»æä¾›ä¸€ç§é¢‡å…·å¸å¼•åŠ›çš„ç­–ç•¥ã€‚
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&mid=2656510012&idx=5&sn=a76e3bede4f8057836362c69718fcedd)

> ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 13 æ¡å†…å®¹ï¼Œè¯¦è§ [æ–‡æœ«](#æ›´å¤š-å…¬ä¼—å·)

</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (10æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨10æ¡ï¼‰

**1.** **GSE305816 èƒ†å›ºé†‡å¤–æ’è›‹ç™½ ABCA1 æ”¯æŒé«“ç³»å…ç–«ç»†èƒçš„æŠ—ç™ŒåŠŸèƒ½ã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€immune
- ğŸ“ **æè¿°**ï¼šContributors : Shruti V Bendre ; Rajendra K C ; Kevin VanBortle ; Erik R NelsonSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusBreast and other solid tumors respond poorly to immune therapy. Myeloid cells (MCs) such as macrophages contribute to resistance. Established clinical evidence links cholesterol to cancer outcomes, with MC function being regulated by cholesterol metabolism. We screened MC-expressed regulators of cholesterol homeostasis linked to survival and identified the cholesterol efflux protein ABCA1. ABCA1 activity increases anti-cancer functions of macrophages: enhancing tumor infiltration, decreasing angiogenic potential, reducing efferocytosis, and improving support of CD8+ T cell activity. Mechanistically, different AKT isoforms are involved, through both PI3K-dependent and independent mechanisms. Highlighting the clinical relevance of our findings are correlations between ABCA1 in macrophages and angiogenic potential, VEGFA, and CD8 T cell abundance and activity. The culmination of these activities was demonstrated through increased tumor growth and metastasis in mice lacking MC-expressed ABCA1. Tumors grown in these mice were also more resistant to immune therapy. Therefore, modulating ABCA1 activity within MCs may represent a novel approach to immune therapy.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305816)

**2.** **GSE248066 ç§‹è‘µæ€»é»„é…®é€šè¿‡ä¸Šè°ƒ LncRNAAL137782 æŠ‘åˆ¶ STAT3/EMT ä¿¡å·é€šè·¯ï¼Œä»è€ŒæŠ‘åˆ¶ç»“ç›´è‚ ç™Œç»†èƒè½¬ç§»**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€pathway
- ğŸ“ **æè¿°**ï¼šContributors : Qian Li ; Hui Zhang ; Yongshan He ; Conghui HanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensTotal flavone of Abelmoschus manihot Lmedic (TFA) is a natural compound known for its anti-inflammatory, analgesic, and antioxidant properties. Despite extensive investigations into the therapeutic potential of TFA, there remains a paucity of reports regarding its impact on cancer treatment. This study aimed to elucidate the effects and mechanisms of TFA in CRC therapy. Subsequently, we employed RNA-seq technology to scrutinize differences in the gene expression profiles between TFA-treated and untreated CRC cells. Our findings underscore that TFA suppresses the growth, migration, and apoptosis of CRC cells. In animal models, TFA inhibits CRC cell growth and reduces hepatic metastasis. Mechanistically, we observed that TFA accomplishes this by upregulating long non-coding RNA AL137782, which, in turn, inhibits the EMT/STAT3 signaling pathway.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248066)

**3.** **GSE287801 å«æ˜Ÿç»†èƒåˆ†åŒ–ä¸­çš„ RNA è°ƒæ§ï¼ˆRNA-seqï¼‰**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šRNA-seq
- ğŸ“ **æè¿°**ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusRNA regulation in satellite cell differentiation
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287801)

**4.** **GSE244343 æ¿€æ´»çš„ ATF6Î± æ˜¯ä¸€ç§å†…è´¨ç½‘åº”æ¿€è¯±å¯¼ç™Œè›‹ç™½ï¼Œå¯ä»£è°¢é™åˆ¶å…ç–«ç›‘è§† [Atf6 KO DEN/HFD çš„æ‰¹é‡ RNA æµ‹åº]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šRNA-seq
- ğŸ“ **æè¿°**ï¼šContributors : Xin Li ; Cynthia Lebeaupin ; Randal J Kaufman ; Mathias HeikenwÃ¤lderSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusHepatocellular carcinoma (HCC) is the fastest growing cause of cancer-related mortality with limited therapies. While endoplasmic reticulum (ER)-stress and the unfolded protein response (UPR) are implicated in HCC, the involvement of the UPR-transducer activating transcription factor 6 alpha (ATF6Î±) remains unclear. In contrast to the well-characterized role of ATF6Î±-activation as an adaptive response to ER-stress, we here demonstrate its hitherto unknown function as an ER stress-inducing oncoprotein and metabolic master-regulator restricting cancer-immunosurveillance. In human HCC, ATF6Î±-activation significantly correlated with reduced patient-survival, tumor-progression, local immunosuppression, and higher recurrence rates of liver-cancer upon hepatectomy. Hepatocyte-specific ATF6Î±-activation in mice induced progressive hepatitis with ER-stress, immunosuppression, and hepatocyte-proliferation. Concomitantly, activated-ATF6Î± increased glycolysis and repressed gluconeogenic enzyme fructose-1,6-bisphosphatase 1 (FBP1). Restoring FBP1 expression prevented ATF6Î±-activation-related pathologies. Prolonged ATF6Î±-activation in hepatocytes triggered hepatocarcinogenesis, intratumoral T-cell infiltration, and nutrient-deprived immune-exhaustion. Immune-checkpoint blockade (ICB) efficiently restored immunosurveillance and dramatically reduced HCC. In line, HCC patients with a significantly higher ATF6Î±-activation signature presented complete response to ICB monotherapy. Targeting Atf6 via germline, hepatocyte-specific ablation, or therapeutic delivery of antisense-oligonucleotides dampened HCC in preclinical liver-cancer models. Thus, prolonged ATF6Î±-activation drives ER-stress, leading to aberrant glucose metabolism-dependent immunosuppression in liver cancer. Our findings propose persistently activated ATF6Î± as an oncoprotein, stratification-marker for liver-cancer ICB, and targetable therapeutic strategy against HCC.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE244343)

**5.** **GSE244342 æ¿€æ´»çš„ ATF6Î± æ˜¯ä¸€ç§å†…è´¨ç½‘åº”æ¿€è¯±å¯¼ç™Œè›‹ç™½ï¼Œå¯ä»£è°¢é™åˆ¶å…ç–«ç›‘è§† [TG-AAV-GFP/CREã€DEN/HFD çš„æ‰¹é‡ RNA æµ‹åº]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šRNA-seq
- ğŸ“ **æè¿°**ï¼šContributors : Xin Li ; Cynthia Lebeaupin ; Randal J Kaufman ; Mathias HeikenwÃ¤lderSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusHepatocellular carcinoma (HCC) is the fastest growing cause of cancer-related mortality with limited therapies. While endoplasmic reticulum (ER)-stress and the unfolded protein response (UPR) are implicated in HCC, the involvement of the UPR-transducer activating transcription factor 6 alpha (ATF6Î±) remains unclear. In contrast to the well-characterized role of ATF6Î±-activation as an adaptive response to ER-stress, we here demonstrate its hitherto unknown function as an ER stress-inducing oncoprotein and metabolic master-regulator restricting cancer-immunosurveillance. In human HCC, ATF6Î±-activation significantly correlated with reduced patient-survival, tumor-progression, local immunosuppression, and higher recurrence rates of liver-cancer upon hepatectomy. Hepatocyte-specific ATF6Î±-activation in mice induced progressive hepatitis with ER-stress, immunosuppression, and hepatocyte-proliferation. Concomitantly, activated-ATF6Î± increased glycolysis and repressed gluconeogenic enzyme fructose-1,6-bisphosphatase 1 (FBP1). Restoring FBP1 expression prevented ATF6Î±-activation-related pathologies. Prolonged ATF6Î±-activation in hepatocytes triggered hepatocarcinogenesis, intratumoral T-cell infiltration, and nutrient-deprived immune-exhaustion. Immune-checkpoint blockade (ICB) efficiently restored immunosurveillance and dramatically reduced HCC. In line, HCC patients with a significantly higher ATF6Î±-activation signature presented complete response to ICB monotherapy. Targeting Atf6 via germline, hepatocyte-specific ablation, or therapeutic delivery of antisense-oligonucleotides dampened HCC in preclinical liver-cancer models. Thus, prolonged ATF6Î±-activation drives ER-stress, leading to aberrant glucose metabolism-dependent immunosuppression in liver cancer. Our findings propose persistently activated ATF6Î± as an oncoprotein, stratification-marker for liver-cancer ICB, and targetable therapeutic strategy against HCC.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE244342)

**6.** **GSE244341 æ¿€æ´»çš„ ATF6Î± æ˜¯ä¸€ç§å†…è´¨ç½‘åº”æ¿€è¯±å¯¼ç™Œè›‹ç™½ï¼Œå¯ä»£è°¢é™åˆ¶å…ç–«ç›‘è§† [TG-AAV-GFP/CRE/FBP1 çš„æ‰¹é‡ RNA æµ‹åº]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šRNAseq
- ğŸ“ **æè¿°**ï¼šContributors : Xin Li ; Cynthia Lebeaupin ; Randal J Kaufman ; Mathias HeikenwÃ¤lderSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusHepatocellular carcinoma (HCC) is the fastest growing cause of cancer-related mortality with limited therapies. While endoplasmic reticulum (ER)-stress and the unfolded protein response (UPR) are implicated in HCC, the involvement of the UPR-transducer activating transcription factor 6 alpha (ATF6Î±) remains unclear. In contrast to the well-characterized role of ATF6Î±-activation as an adaptive response to ER-stress, we here demonstrate its hitherto unknown function as an ER stress-inducing oncoprotein and metabolic master-regulator restricting cancer-immunosurveillance. In human HCC, ATF6Î±-activation significantly correlated with reduced patient-survival, tumor-progression, local immunosuppression, and higher recurrence rates of liver-cancer upon hepatectomy. Hepatocyte-specific ATF6Î±-activation in mice induced progressive hepatitis with ER-stress, immunosuppression, and hepatocyte-proliferation. Concomitantly, activated-ATF6Î± increased glycolysis and repressed gluconeogenic enzyme fructose-1,6-bisphosphatase 1 (FBP1). Restoring FBP1 expression prevented ATF6Î±-activation-related pathologies. Prolonged ATF6Î±-activation in hepatocytes triggered hepatocarcinogenesis, intratumoral T-cell infiltration, and nutrient-deprived immune-exhaustion. Immune-checkpoint blockade (ICB) efficiently restored immunosurveillance and dramatically reduced HCC. In line, HCC patients with a significantly higher ATF6Î±-activation signature presented complete response to ICB monotherapy. Targeting Atf6 via germline, hepatocyte-specific ablation, or therapeutic delivery of antisense-oligonucleotides dampened HCC in preclinical liver-cancer models. Thus, prolonged ATF6Î±-activation drives ER-stress, leading to aberrant glucose metabolism-dependent immunosuppression in liver cancer. Our findings propose persistently activated ATF6Î± as an oncoprotein, stratification-marker for liver-cancer ICB, and targetable therapeutic strategy against HCC.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE244341)

**7.** **GSE292906 LUMINIDEPENDENS è›‹ç™½æ˜¯æ‹Ÿå—èŠ¥ä¸­è½¬å½•çš„ä¸€èˆ¬æŠ‘åˆ¶å› å­ [RNA-Seq 2]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šRNA-seq
- ğŸ“ **æè¿°**ï¼šContributors : Clara Bergis-Ser ; Qingyi Wang ; Xiaoning He ; Maherun Nisa ; Vickie Kaiser ; Christelle Mazubert ; Jeannine Drouin-Wahbi ; Rim Brik-Chaouche ; Layla Chmaiss ; Jeele Van Leene ; Geert de Jaeger ; Jose Gutierrez-Marcos ; Catherine Bergounioux ; Clara Richet-Bourbousse ; David Latrasse ; Moussa Benhamed ; CÃ©cile RaynaudSeries Type : Expression profiling by high throughput sequencingOrganism : Arabidopsis thalianaGenomic integrity is constantly challenged by transcription/replication conflicts, a major source of replication stress and instability across all life forms. While extensive studies have uncovered transcription/replication conflicts resolution mechanisms in animals, yeast, and prokaryotes, their counterparts in plants remain largely unexplored. Through a forward genetic screen, we identified the LUMINIDEPENDENS (LD) protein, previously known for regulating the flowering repressor FLC, as a key player in mitigating replication stress in plants. Strikingly, transcriptomic analyses reveal that loss of LD results in the upregulation of over 13,000 genes, establishing LD as a global transcriptional repressor. Consistent with this role, LD binds a substantial portion of the Arabidopsis genome and interacts with the MED18 subunit of the Mediator complex to modulate RNA polymerase II phosphorylation. These findings uncover a fundamental function of LD in fine-tuning transcription genome-wide, with an additional role in suppressing transcription/replication conflicts by locally dampening transcription and promoting replication fork progression. Our work highlights a previously unrecognized genome-protective strategy in plants, opening new avenues for understanding transcription/replication conflict management in eukaryotic systems.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292906)

**8.** **GSE292381 LUMINIDEPENDENS è›‹ç™½æ˜¯æ‹Ÿå—èŠ¥ä¸­è½¬å½•çš„ä¸€èˆ¬æŠ‘åˆ¶å› å­ [LD ChIP-Seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šChIP-seq
- ğŸ“ **æè¿°**ï¼šContributors : Clara Bergis-Ser ; Qingyi Wang ; Xiaoning He ; Maherun Nisa ; Vickie Kaiser ; Christelle Mazubert ; Jeannine Drouin-Wahbi ; Rim Brik-Chaouche ; Layla Chmaiss ; Jeele Van Leene ; Geert de Jaeger ; Jose Gutierrez-Marcos ; Catherine Bergounioux ; Clara Richet-Bourbousse ; David Latrasse ; Moussa Benhamed ; CÃ©cile RaynaudSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Arabidopsis thalianaGenomic integrity is constantly challenged by transcription/replication conflicts, a major source of replication stress and instability across all life forms. While extensive studies have uncovered transcription/replication conflicts resolution mechanisms in animals, yeast, and prokaryotes, their counterparts in plants remain largely unexplored. Through a forward genetic screen, we identified the LUMINIDEPENDENS (LD) protein, previously known for regulating the flowering repressor FLC, as a key player in mitigating replication stress in plants. Strikingly, transcriptomic analyses reveal that loss of LD results in the upregulation of over 13,000 genes, establishing LD as a global transcriptional repressor. Consistent with this role, LD binds a substantial portion of the Arabidopsis genome and interacts with the MED18 subunit of the Mediator complex to modulate RNA polymerase II phosphorylation. These findings uncover a fundamental function of LD in fine-tuning transcription genome-wide, with an additional role in suppressing transcription/replication conflicts by locally dampening transcription and promoting replication fork progression. Our work highlights a previously unrecognized genome-protective strategy in plants, opening new avenues for understanding transcription/replication conflict management in eukaryotic systems.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292381)

**9.** **GSE290980 é¶å‘åä¹‰å¯¡æ ¸è‹·é…¸æ²»ç–—æŒ½æ•‘è„Šé«“æ€§è‚Œèç¼©ç—‡ç±»å™¨å®˜çš„å‘è‚²å¼‚å¸¸ [scRNA-seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šscRNA
- ğŸ“ **æè¿°**ï¼šContributors : Irene Faravelli ; Paola Rinchetti ; Monica Tambalo ; Illia Simutin ; Lisa Mapelli ; Sara Mancinelli ; Matteo Miotto ; Mafalda Rizzuti ; Andrea Dâ€™Angelo ; Chiara Cordiglieri ; Giulia Forotti ; Clelia Peano ; Paolo Kunderfranco ; Luca Calandriello ; Giacomo P Comi ; Elvezia Paraboschi ; Eleonora Pali ; Francesca Beatrice ; Egidio Dâ€™Angelo ; Serge Przedborski ; Monica Nizzardo ; Simona Lodato ; Stefania CortiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensSpinal muscular atrophy (SMA) is a severe neurological disease caused by mutations in the SMN1 gene, characterized by early onset and degeneration of lower motor neurons.Understanding early neurodevelopmental defects in SMA is crucial for optimizing therapeutic interventions. Using spinal cord and cerebral organoids generated from multiple SMA type I donors, we revealed widespread disease mechanisms beyond motor neuron degeneration. Single-cell transcriptomics uncovered pervasive alterations across neural populations, from progenitors to neurons, demonstrating SMN-dependent dysregulation of neuronal differentiation programs. Multi-electrode array analysis identified consistent hyperexcitability in both spinal and brain organoids, establishing altered electrical properties as a central nervous system-wide feature of pathogenesis. Early administration of an optimized antisense oligonucleotide (ASO) that restored SMN levels rescued morphological and functional deficits in spinal cord organoids across different genetic backgrounds. Importantly, this early intervention precisely corrected aberrant splicing in newly identified SMN1 targets enriched at critical nodes of neuronal differentiation. Our findings demonstrate that early developmental defects are core features of SMA pathogenesis that can be prevented by timely therapeutic intervention, providing new insights for optimizing treatment strategies.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290980)

**10.** **GSE290979 é¶å‘åä¹‰å¯¡æ ¸è‹·é…¸æ²»ç–—æŒ½æ•‘è„Šé«“æ€§è‚Œèç¼©ç—‡ç±»å™¨å®˜çš„å‘è‚²å¼‚å¸¸ [bulk RNA-seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šRNA-seq
- ğŸ“ **æè¿°**ï¼šContributors : Irene Faravelli ; Paola Rinchetti ; Monica Tambalo ; Illia Simutin ; Lisa Mapelli ; Sara Mancinelli ; Matteo Miotto ; Mafalda Rizzuti ; Andrea Dâ€™Angelo ; Chiara Cordiglieri ; Giulia Forotti ; Clelia Peano ; Paolo Kunderfranco ; Luca Calandriello ; Giacomo P Comi ; Elvezia Paraboschi ; Eleonora Pali ; Francesca Beatrice ; Egidio Dâ€™Angelo ; Serge Przedborski ; Monica Nizzardo ; Simona Lodato ; Stefania CortiSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensSpinal muscular atrophy (SMA) is a severe neurological disease caused by mutations in the SMN1 gene, characterized by early onset and degeneration of lower motor neurons.Understanding early neurodevelopmental defects in SMA is crucial for optimizing therapeutic interventions. Using spinal cord and cerebral organoids generated from multiple SMA type I donors, we revealed widespread disease mechanisms beyond motor neuron degeneration. Single-cell transcriptomics uncovered pervasive alterations across neural populations, from progenitors to neurons, demonstrating SMN-dependent dysregulation of neuronal differentiation programs. Multi-electrode array analysis identified consistent hyperexcitability in both spinal and brain organoids, establishing altered electrical properties as a central nervous system-wide feature of pathogenesis. Early administration of an optimized antisense oligonucleotide (ASO) that restored SMN levels rescued morphological and functional deficits in spinal cord organoids across different genetic backgrounds. Importantly, this early intervention precisely corrected aberrant splicing in newly identified SMN1 targets enriched at critical nodes of neuronal differentiation. Our findings demonstrate that early developmental defects are core features of SMA pathogenesis that can be prevented by timely therapeutic intervention, providing new insights for optimizing treatment strategies.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290979)


</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ”¬ æœŸåˆŠæ–‡ç«  (1æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰

**1.** **å‹˜è¯¯è¡¨ï¼šæ¥å—å…¨èº«æ€§ç™Œç—‡æ²»ç–—çš„è€å¹´æ‚£è€…è„†å¼±æ€§çš„å®é™…è¯„ä¼°å’Œç®¡ç†ï¼šASCO æŒ‡å—æ›´æ–°**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šç™Œç—‡
- ğŸ“ **æè¿°**ï¼šSecret hovertext: ä¸´åºŠè‚¿ç˜¤å­¦æ‚å¿—ï¼Œå°åˆ·å‰ã€‚
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://m.x-mol.com/paper/1989792451576049664/t)


</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (1æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰

**1.** **ç¥ç»ç§‘å­¦å®¶å‘ç°å¯èƒ½å»¶ç¼“è¡°è€çš„å…ç–«ç»†èƒã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šimmuneã€aging
- ğŸ“ **æè¿°**ï¼šA newly recognized set of T helper cells seems to guard against aging by eliminating harmful senescent cells. Their presence in supercentenarians suggests they may be a key to maintaining a healthier, age-balanced immune system.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.sciencedaily.com/releases/2025/11/251115095926.htm)


</div>

</details>

## ğŸ“Š å…³é”®è¯ç»Ÿè®¡

| å…³é”®è¯ | å‡ºç°æ¬¡æ•° |
|--------|----------|
| å•ç»†èƒ | 9 |
| å…ç–« | 5 |
| RNA-seq | 5 |
| è‚¿ç˜¤ | 4 |
| è¡°è€ | 4 |
| ç™Œç—‡ | 3 |
| ç”Ÿä¿¡ | 2 |
| æµ‹åº | 2 |
| cancer | 2 |
| immune | 2 |
| ç©ºé—´è½¬å½•ç»„ | 2 |
| è½¬å½•ç»„ | 2 |
| ç¥ç» | 1 |
| ä»£è°¢ | 1 |
| é€šè·¯ | 1 |
| aging | 1 |
| RNAseq | 1 |
| å…ç–«å¾®ç¯å¢ƒ | 1 |
| å¿ƒè„ | 1 |
| åŸºå› ç»„ | 1 |

---

## ğŸ“ æ›´å¤šå†…å®¹

<details>
<summary><a name="æ›´å¤š-å…¬ä¼—å·"></a>ğŸ“° å…¬ä¼—å· å…¶ä»–å†…å®¹ (13æ¡)</summary>

<div class="details-content" markdown="1">

- [è¡¨è§‚åŸºå› ç»„ | Nat.Genet. | æ€¥æ€§ç™½è¡€ç—…çš„å¿«é€Ÿè¡¨è§‚åŸºå› ç»„åˆ†ç±»](https://mp.weixin.qq.com/s?__biz=Mzg5NjgxNjkwOA==&mid=2247503135&idx=1&sn=f1ed610de8f0205f3dfe4a0d9adefd9b)
- [å•ç»†èƒæµ‹åºå’Œæ·±åº¦å­¦ä¹ ç³»åˆ—ä¸€ï¼šç†è§£åŸºç¡€åˆ†ææµç¨‹ä¸­çš„æ¦‚å¿µ](https://mp.weixin.qq.com/s?__biz=MzI4MjY5ODI1Nw==&mid=2247496730&idx=1&sn=1d4464b05f6b68af6d8a3aae55b39a0e)
- [æ‰‹æŠŠæ‰‹æ•™ä½ å·ç§¯ç¥ç»ç½‘ç»œ(CNN)æ¨¡å‹ï¼šæ¨¡å‹æ€§èƒ½è¯„ä¼°å’Œé¢„æµ‹ç­–ç•¥](https://mp.weixin.qq.com/s?__biz=MzUzMTEwODk0Ng==&mid=2247538098&idx=1&sn=b71bbfed1e5d7bd5b9e24412ec555110)
- [è¯¦è§£ï¼šè¡€ç³–ä»£è°¢è¿‡ç¨‹](https://mp.weixin.qq.com/s?__biz=MzYyNDMwNjg3Nw==&mid=2247484052&idx=1&sn=d738043359c0e4192f17cf56eaf9958f)
- [çº¯ä»£ç å®æ“ï¼å•ç»†èƒå †å å°æç´å›¾åä¸½æ¥è¢­ï¼ï¼](https://mp.weixin.qq.com/s?__biz=Mzg5MDk3Mzg4OA==&mid=2247498477&idx=1&sn=05454e05b58a026ce1af7c86bd62ef27)
- [å†…å­˜èŠ‚çº¦è¿‘70å€ï¼Œç¬”è®°æœ¬å°±èƒ½è·‘400ç™¾ä¸‡å•ç»†èƒæ•°æ®ï¼Œè¿ç®—é€Ÿåº¦å¤§å¹…åº¦æå‡ï¼Œçœ‹çœ‹BPCellsè¿™ä¸ªæ–°æ–¹æ³•](https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&mid=2247495581&idx=1&sn=87df56d4017465325e618711e6126f5c)
- [11åˆ†è·³è¿‡æ— æ„ä¹‰çš„æµ‹åºï¼ç›´å¥”å¾®ç”Ÿç‰©ç»„+é¶å™¨å®˜å±éšœ+ç–¾ç—…è¡¨å‹çš„æ ¸å¿ƒæœºåˆ¶ï¼](https://mp.weixin.qq.com/s?__biz=MzkyNzcxMjEyMg==&mid=2247497931&idx=1&sn=7dd8cddcae53cd4a8fadcc3e71e775f3)
- [æœ€æ–°15åˆ†æ³›ç™Œè‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒå›¾è°±ï¼Œå›¾è°±æ„å»ºéœ€è¦å¤ªå¤šèƒŒæ™¯çŸ¥è¯†ï¼Œå€¼å¾—æ”¶è—ï¼](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503966&idx=4&sn=ab779c0d8202e1c12bbf88b1190f4566)
- [uniLUNGï¼šç›®å‰æœ€å…¨é¢çš„äººç±»è‚ºéƒ¨å•ç»†èƒå›¾è°±ï¼ˆæœ€æ–°å‘è¡¨ï¼Œ2025.11.13ï¼‰](https://mp.weixin.qq.com/s?__biz=MzAxMDkxODM1Ng==&mid=2247547035&idx=1&sn=397c1209f499c819e2440de165b79d12)
- [æŠ—è‚¿ç˜¤çš„10ä¸ªç»†èƒå› å­](https://mp.weixin.qq.com/s?__biz=Mzg2OTczNjI0OQ==&mid=2247528882&idx=1&sn=76b607a84a29f976e6c7058daece50e9)
- [é‡ç£…ç ”ç©¶ï¼ä¸­å±±å¤§å­¦æä¼Ÿå¿ &æ¸…åå¤§å­¦å¼ å­¦å·¥å›¢é˜Ÿæ„å»ºç›®å‰æœ€å…¨é¢çš„äººç±»è‚ºéƒ¨å•ç»†èƒå›¾è°±ï¼šæ•´åˆ62ä¸ªæ•°æ®é›†ï¼Œ920ä¸‡ç»†èƒï¼Œ1807åæ ·æœ¬](https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&mid=2656510012&idx=1&sn=fea11f84c61818909b8a8e1bd360a6cf)
- [æ–°ä¸€ä»£ Chromium Flexï¼Œèµ‹èƒ½ç§‘å­¦å®¶å®ç°å•ç»†èƒç ”ç©¶çš„è§„æ¨¡åŒ–æ–°é£è·ƒ](https://mp.weixin.qq.com/s?__biz=MzU1MDk1NTY5MA==&mid=2247540986&idx=1&sn=2f5b88c9a5b74914bd4fdbddcefc6b6a)
- [æŠ—çš®è‚¤è¡°è€çš„ç§‘å­¦ä¹‹é“ä¸å†…åœ¨æœºç†](https://mp.weixin.qq.com/s?__biz=MzkxODY4NDEwMA==&mid=2247489928&idx=1&sn=a0418042d14cd9cc5d80ef5b81bf4009)

</div>

</details>

---

*ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-11-17 21:44*  
*ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ*